top button
    Got Questions


Global IoT Summit 2018
Oct 31, 2018
The Leela Palace, Bangalore



    Connect to us
      Facebook Login
      Site Registration Why to Join

Facebook Login
Site Registration

Schizophrenia Drugs Market Outlook, Trend, Growth and Share Estimation Analysis

0 votes
3 views

A report by Transparency Market Research states that global schizophrenia drugs market is projected to witness a substantial growth in the duration of 2019 to 2027. According to the expert analysis of the global schizophrenia drugs market by Transparency Market Research, the market is expected to witness this growth due to growing adoption of several new methods of polypharmacology which is helping them develop new drugs. Additionally, the global schizophrenia drugs market is also growing rapidly due to pacing development of multi-target drugs in order to cure several disorders and disease with single medicine.

Analysts Predicts a Massive Hike in Revenue

As per the experts, the global schizophrenia drugs market is projected to reach to the value of US$ 15.7 bn by the end of 2027. The growth of global schizophrenia drugs market is attributed to the developments that are done to improve the healthcare infrastructure in several countries. The schizophrenia drugs market is projected to witness a 4% CAGR to achieve this value. The experts also predict that there are ample of opportunities to grow. This means that the players have plenty of opportunities as the schizophrenia drugs market stood at US$ 11.1 bn during 2018.

Planning To Lay Down Future Strategy? Request Brochure Of Schizophrenia Drugs Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=67820

Pharmaceutical Companies’ Developments to Boost the Growth

Pharmaceutical companies are developing new drugs that can cure multiple diseases at once. These developments are major factor that are boosting the growth of global schizophrenia drugs market. Additionally, the technological developments that several pharmaceutical companies, the global schizophrenia drugs market is further experiencing a major growth from 2019 to 2027. These developments to help the players of global schizophrenia drugs market are stimulating the new drug discoveries. These discoveries shall further boost the growth of global schizophrenia drugs market.

Development of Generic Drug to Boost the Growth

The global schizophrenia drugs market is experiencing several generic drug developments. These developments aim to develop drugs that can conveniently cure several diseases. Based on these developments the players can generate huge revenue that can help them secure a stronger position in the global schizophrenia drugs market. However, the competition in the market is quite high and tough, which consequently makes the entry if new player in global schizophrenia drugs market quite difficult. To overcome this situation, the new players are merging and collaborating with the established player of global schizophrenia drugs market.

With these strategies the new players can gain access to resources that can help them gain sustainability and stability in global schizophrenia drugs market.

To Obtain All-Inclusive Information On Forecast Analysis Of Schizophrenia Drugs Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=67820

North America Dominates the Geographical Front

On the basis of geography, North America dominates other regions such as Asia Pacific, South America, and Europe. The domination of the region is the result of growing number of pharmaceutical companies in U.S. and Canada. Also, the improving healthcare infrastructure in these countries also supports the domination of North America in global schizophrenia drugs market from 2019 to 2027.

posted Feb 12 by Rohini Chaudhari

  Promote This Article
Facebook Share Button Twitter Share Button Google+ Share Button LinkedIn Share Button Multiple Social Share Button

Related Articles
0 votes

The majority of shares of the global dyslipidemia drugs market is concentrated among a handful of companies. The top five companies account for the combined share of 74.4% in 2014, finds Transparency Market Research. These players are Abbott Laboratories, Daiichi Sankyo Company, Ltd., Pfizer, Inc., Merck & Co., Inc., and AstraZeneca plc. TMR observes that the leading players exercise a substantial clout in the global market on account of the exclusive rights they hold over blockbuster drugs for managing dyslipidemia. They are also pouring in sizeable money in research and development activities, which is helping them retain their lead.

The global dyslipidemia drugs market is anticipated to stagnate at a CAGR of -10.3% in between the forecast period of 2015 to 2023. The market was worth US$17.85 billion in 2014 and the negative CAGR will lead the demand to shrink to US$6.88 billion by 2023 end.

The stagnating demand for dyslipidemia drugs across the globe is attributed to the patent expiry for some blockbuster drugs along with the rising availability of generic drugs.

Planning To Lay Down Future Strategy? Request Brochure Of Dyslipidemia Drugs Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1535

The various types of dyslipidemia drugs are statins, bile acid resins, fibric acid and omega-3 fatty acid derivatives, niacins, combination drugs, and cholesterol absorption inhibitors. Of these, the segment of fibrates and omega-3 fatty acid derivatives leads the pack and will decline at the lowest rate of 1.6% during the forecast period. The substantial number of government approvals for this class of drug is boosting the market.

Geographically, Europe is the most lucrative region expected to decline at a CAGR of 9.9%. The rising incidence of dyslipidemia among the regional population will offset a part of the revenue loss being witnessed in the global market.

Substantial Risk Factor for Diabetes and Cardiovascular Diseases likely to Catapult Demand for Dyslipidemia Drugs

The global dyslipidemia market is positively affected by the rising demand for drugs for treating secondary dyslipidemia, with diabetes and obesity occupying a key role in disease development. The substantial risk that the condition has on the development of cardiovascular diseases is a key factor accentuating the demand for dyslipidemia drugs. Efforts by caregivers to prevent future cardiovascular (CVD) diseases in worldwide population augur well for the market. The significant role that dyslipidemia management is occupying in CVD prevention is boosting the market.

To Obtain All-Inclusive Information On Forecast Analysis Of Dyslipidemia Drugs Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1535

The rise in demand for prescription drugs based on omega-3 fatty acid derivatives and fibrates will add to global revenues over the assessment period. The rising incidence of type 2 diabetes in various parts of the world raises the risk of dyslipidemia considerably, which is propelling the demand for the drugs.

Expiration of Blockbuster Drugs has Wide Repercussions on Growth, However, Rising Obese Population augurs Well

However, the expansion of the market is hindered by a serious constraint brought by expiration of several blockbuster drugs and the proliferation of generic drugs to manage the condition of dyslipidemia. This is exerting considerable adverse effect on the global market revenues. Be that it may, the market may limp back to growth on the promising demand for such drugs from an emerging population of obese in various parts of the world. The high mortality of cardiovascular diseases, coupled with the rising awareness in health-conscious populations, augurs well for the market.

0 votes

Transparency Market Research (TMR) has published a new report on the systemic lupus erythematosus treatment market for the forecast period of 2019–2027. According to the report, the global systemic lupus erythematosus treatment market was valued at ~US$ 1.7 Bn in 2018, and is projected to expand at a CAGR of ~7% from 2019 to 2027.

Systemic Lupus Erythematosus Treatment Market: Overview

  • Growth of the global systemic lupus erythematosus treatment market can be attributed to rise in the incidence of systemic lupus erythematosus, and promising drug pipeline and approvals.
  • North America dominated the global systemic lupus erythematosus treatment market in 2018, and the trend is anticipated to continue during the forecast period. Highly structured healthcare industry, early new product adoption, and the presence of major market players are expected to drive the market in North America.
  • Asia Pacific is expected to be a highly lucrative market for systemic lupus erythematosus treatment, expanding at a high CAGR during the forecast period.

Immunosuppressive Drugs to Dominate Market

  • Based on drug, the global systemic lupus erythematosus treatment market has been divided into antimalarial drugs, non-steroidal anti-inflammatory drugs (NSAIDS), corticosteroids, immunosuppressive drugs, and others (biologics, B-cell modulators, etc.).
  • The immunosuppressive drugs segment dominated the global systemic lupus erythematosus treatment market in 2018, and the trend is likely to continue during the forecast period.
  • Immunosuppressive drugs such as azathioprine, cyclophosphamide, and methotrexate help control inflammation and the overactive immune system in the treatment of SLE. Furthermore, increase in the popularity of methotrexate as a treatment option is likely to boost the growth of this segment.
  • The immunosuppressive drugs segment can be further segmented into azathioprine, cyclophosphamide, methotrexate, and others. In terms of immunosuppressive drugs, the azathioprine sub-segment is anticipated to dominate the market.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=73932

Oral Mode of Delivery to be Popular

  • In terms of mode of delivery, the global systemic lupus erythematosus treatment market can be divided into intravenous, subcutaneous, and oral.
  • The oral segment dominated the global systemic lupus erythematosus treatment market, due to an increase in the preference for self-administration of drugs such as immunosuppressive drugs, antimalarial drugs, and corticosteroids. This, in turn, is projected to drive the segment during the forecast period.
  • Furthermore, major market players are focusing on the launching of new products in the tablet and capsule form. This is likely to boost the growth of the segment during the forecast period.
  • The intravenous segment is expected to be a highly lucrative segment of the market during the forecast period. The intravenous route helps in the immediate delivery of drug, and since the delivery is into a vein, the drug starts working immediately. Moreover, drug degradation is less as compared to the oral route of administration.

Retail Pharmacies Accounted for Major Share of Market

  • Based on distribution channel, the global systemic lupus erythematosus treatment market has been segmented into hospital pharmacies, retail pharmacies, and online sales.
  • The retail pharmacies segment dominated the global systemic lupus erythematosus treatment market in terms of revenue in 2018, and the trend is projected to continue during the forecast period. Increase in the number of retail pharmacy stores across the globe, availability of new products in retail stores, and availability of most of the drugs, such as NSAIDS, antimalarial drugs, and corticosteroids, as OTC drugs in retail stores, are likely to propel this segment during the forecast period.
  • Hospital pharmacies is expected to be the second-most lucrative segment of the global systemic lupus erythematosus treatment market during the forecast period. The segment is expected to expand at a significant CAGR from 2019 to 2027,due to an increase in the demand for recently launched new products for systemic lupus erythematosus treatment.

Buy Now Systemic Lupus Erythematosus Treatment Market Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=73932&ltype=S

North America to Dominate Global Market

  • In terms of region, the global systemic lupus erythematosus treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global systemic lupus erythematosus treatment market in 2018, followed by Europe.
  • North America accounted for a major share of the global systemic lupus erythematosus treatment market in 2018, owing to an increase in the use of systemic lupus erythematosus treatment products, especially for various symptoms of the disease. Additionally, the launch of new products by major pharmaceutical manufacturers fuels the market in this region.
  • The systemic lupus erythematosus treatment market in Asia Pacific is likely to expand at a high CAGR from 2019 to 2027. This can be attributed to an increase in the prevalence of systemic lupus erythematosus, improving healthcare infrastructure in terms of better facilities, and rise in the demand for advanced products. According to a latest study, the prevalence was in the range of 4.3 to 45.3/100,000 person per year.

Systemic Lupus Erythematosus Treatment Market: Competitive Landscape

  • The global systemic lupus erythematosus treatment market is fragmented in terms of number of players.
  • Key players operating in the global market include GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Pfizer, Inc., AstraZeneca, Merck & Co., Inc., Bristol-Myers Squibb Company, Anthera Pharmaceuticals, Inc., ImmuPharma PLC, and Aurinia Pharmaceuticals, Inc.

More Trending Reports by Transparency Market Research –

Non-invasive Prenatal Testing Market: prnewswire.com/news-releases/non-invasive-prenatal-testing-market-to-cross-us-5-000-million-by-2027—says-tmr-300865294.html

Global Wound Healing Market: prnewswire.com/news-releases/global-wound-healing-market-to-reach-over-us-350-billion-by-2025-says-tmr-676809663.html

0 votes

As per the research conducted by Transparency Market Research, the diabetes devices market has been noted to have a consolidated vendor landscape globally. F. Hoffmann-La Roche Ltd. Medtronic plc, Sanofi S.A., Eli Lilly and Company, and Novo Nordisk A/S, are a few of the main players in the diabetes devices market globally and the main reason behind their upper hand on this market is the variety they offer in their products.

Most of these players are now focusing on entering in the developing markets and make use of the growth prospects available there because of economic development. However, manufacturing of basic and cheaply priced diabetes devices will be their main plan. One of the main plans and areas of focus for the manufacturers will be expanding geographically  by merging with the other players, as well as partnerships for their benefits.

Planning To Lay Down Future Strategy? Request Brochure Of Diabetes Devices Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14

As per the reports of Transparency Market Research, the diabetes devices market is predicted to account for a total of US$66,053.1 mn by 2025, whereas in the year 2016 it was accounted for a total of US$37220.8 mn globally thereby growing at a CAGR of 6.7%. Although there are many items that help in managing diabetes, glucose monitoring devices and the different items that fall under it are predicted to lead the diabetes devices market globally. In terms of the income generated, the glucose meters segment accounted for a total of 59.1% of the total income generated in the year 2016 globally. On the basis of geography, North America is the dominating market because of the existence of advanced as well as up to date healthcare systems.

Increasing Stress and Consumption of Alcohol Behind High Incidences of Diabetes 

Primarily, the demand for global diabetes devices market is carried forward by the growth in the number of patients diagnosed with diabetes throughout the globe. A few major reasons behind the growth in the occurrence of diabetes among patients is the stress people take, consuming alcohol in large quantities, unhealthy food consumption, as well as because of lifestyle that does not consist of much physical activities. In the last few years, the growth in the number of patients suffering from diabetes has boosted the requirement for diabetes devices.

To Obtain All-Inclusive Information On Forecast Analysis Of Diabetes Devices Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=14

New Novel Insulin Delivery Devices to Drive Demand

Due to the existence of devices like testing strips, continuous monitoring devices, lancets, self-monitoring blood glucose metres, that are cost effective as well, have a healthy impact on the market in general. Plus, the growth and awareness regarding managing diabetes is expected to bolster the diabetes devices market. Because of the entrants of new products in the market, the diabetes devices market is said to have been further boosted. Like for example, the new novel insulin delivery device is predicted to increase the requirements for diabetes devices for home disease management.

0 votes

Transparency Market Research (TMR) has published a new report titled, “Smart Insulin Pens Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027”. According to the report, the global smart insulin pens market was valued at US$ 29.2 Mn in 2018. It is projected expand at a CAGR of 10.3% from 2019 to 2027. Increase in the prevalence of diabetes, rise in awareness about chronic diseases, such as diabetes, and surge in adoption of connected medical devices are anticipated to augment the global market between 2019 and 2027.

Smart insulin pens are used to deliver insulin for the treatment of type 1 and type 2 diabetes. Smart insulin pens have additional features such as memory function, time and dose recorder, and data transfer. Rise in prevalence of both type of diabetes in children and adults, due to obesity and changing lifestyle and dietary habits, is a key factor that is anticipated to drive the global market for smart insulin pens. Additionally, technological advancements and integration of glucose monitoring and therapeutics for better diabetes management are likely to propel the global smart insulin pens market. However, availability of alternatives for insulin delivery is anticipated to restrain the global market.

The report offers detailed segmentation of the global smart insulin pens market based on product, connectivity type, application, and distribution channel. The market has also been segmented based on region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). Adoption of technological advancements and increase in prevalence of diabetes are likely to drive the global smart insulin pens market.

Request a PDF Sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=35705

Adaptors for conventional pens segment to account for leading share, while smart insulin pens segment expand significantly

In terms of product, the adaptors for conventional pens segment accounted for a leading share of the global market in 2018, and the trend is anticipated to continue during the forecast period. Increase in prevalence of diabetes in people of all ages across the globe is projected to boost the segment during the forecast period. Expansion of the smart insulin pens segment is attributed to technological advancements such as memory function and accurate dose administration.

Technological advancements in smart insulin pen to propel market

Emerging technologies in smart insulin pens are projected to boost the global smart insulin pens market during the forecast period. iSenz is an adaptor for smart insulin pens that possess a feature to detect the insulin level, by scanning. It provides the correct angles for injections in order to optimize the injection sites for diabetes. Easylog is an adaptor for insulin pens connected via the internet. This product provides the right dose and offers better comfort to the patient for the treatment of chronic diseases such as diabetes. InsulCheck, is cap for insulin pens that contains a sensor to track pen usage and temperature.

Buy Now Smart Insulin Pens Market Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=35705&ltype=S

North America to be highly lucrative smart insulin pens market

North America has a large number of smart insulin pens approved for the treatment of diabetes. In the U.S., significant increase in the prevalence of diabetes is likely to propel the region’s leading share of the global market during the forecast period. Additionally, product launches and approval for smart insulin pens are anticipated to drive the market in the region.

Product launches by key players and patent approvals to boost market

The report also provides profiles of leading players operating in the global smart insulin pens market. These include Novo Nordisk A/S, Sanofi (sanofi-aventis US LLC), Eli Lilly and Company, Companion Medical, Emperra GmbH E-Health Technologies, Diabnext, Jiangsu Delfu medical device Co.,Ltd, BERLIN-CHEMIE, DIAMESCO CO., Ltd., and Patients Pending Ltd (Bigfoot Biomedical Inc.). In July 2018, Companion Medical, a provider of advanced technological products for diabetes, received approval from Food and Drug Administration for InPen in the U.S. This product approval enabled the company to strengthen its digital diabetes products portfolio in the U.S. In March 2018, sanofi-aventis U.S. LLC received approval from U. S. Food and Drug Administration for Toujeo Max SoloStar. This product approval enabled the company to strengthen its product portfolio.

More Trending Reports by Transparency Market Research –

ePharmacy Market: prnewswire.com/news-releases/epharmacy-market-to-reach-us128-billion-by-2023-transparency-market-research-560938961.html

Canada Home Healthcare Market: prnewswire.com/news-releases/canada-home-healthcare-market-set-to-reach-us1894-bn-by-the-end-of-2020-transparency-market-research-565741581.html

0 votes

The North America facial injectables market is expected to gather momentum from the growing adoption of facial injectables in skin rejuvenation treatments in the regional population. The marked affordability of a range of such treatments is a key factor propelling growth in the regional market. Advances in cosmetology have improved the prospects of minimally invasive surgeries for facial skin rejuvenation. Expanding array of long-lasting facial fillers has helped key players in the North America facial injectables market reap large revenue gains over the past several years. Strides in the overall medical aesthetic market are proportionately advancing progress in the North America facial injectables market

The North America facial injectables market was estimated at US$2.1 billion in 2015 and is expected to climb to a valuation of US$5.8 billion by the end of 2024. The regional market is projected to clock a promising CAGR of 12.0% during 2016 – 2024. Changing concepts of the role of skin rejuvenation in beauty and aesthetics among worldwide populations are keeping the regional market increasingly lucrative.

Planning To Lay Down Future Strategy? Request Brochure Of Facial Injectables Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=18515

Some of the top players in the North America facial injectables are Ipsen Group, Galderma S.A., Prollenium Medical Technologies Inc., and Merz Pharma & Co. KGaA.

Among the various countries, a leading chunk of the regional revenues come from the U.S. The status quo is likely to not change in coming years. The vast uptake botulinum toxins and dermal fillers in the U.S. population is a key factor behind the dominance of this country market.

Expanding Array of Dermal Filler Formulations Expand Potential in Cosmetology

Growing demand for facial fillers to reverse aging among the worldwide populations is one of the factor catalyzing the revenue potential of the North America facial injectables market. A range of dermal filler formulations have shown potential in correcting facial wrinkles and folds. Advances in in cosmetology have seen the advent of promising synthetic products such as those made with polymers that find use in anti-aging. A number of these formulations are being endorsed by persons from the media and entertainment industry. This has also bolstered the prospective demand in the regional market.

To Obtain All-Inclusive Information On Forecast Analysis Of Facial Injectables Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=18515

Concerns of Safety Significant

Despite the vast potential that facial injectables hold for skin rejuvenation and anti-aging, concerns of safety and side-effects galore. A reason for this can be that clinical trials approve the use of facial injectables only for certain indications rather than what they are being currently considered for among dermatologists. Proliferating off-label uses in regional population may hinder the North America facial injectables market to realize its true potential. Nonetheless, advances in cosmetic and medical dermatology are likely to address a number of these concerns in their strides.

The presence of board-certified dermatologists and surgeons in developed countries of North America is a key factor cementing the potential of the regional market. In recent years, there have been seemingly rising demands for neuromodulators and dermal fillers among older women over 40. The growing trend has opened new revenue streams for players in the North America facial injectables market.

...